Brief: Santhera And ReveraGen To Present New Data With Vamorolone
June 9 (Reuters) - SANTHERA PHARMACEUTICALS HOLDING AG
SANN.S :
* SANTHERA AND REVERAGEN TO PRESENT NEW DATA WITH VAMOROLONE
AT
2022 PARENT PROJECT MUSCULAR DYSTROPHY CONFERENCE
Source text for Eikon: ID:nGNE2nLT6V
Further company coverage: SANN.S
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Santhera Pharmaceuticals Holding AG
See all newsSwitzerland's Santhera Pharma H1 revenue soars on AGAMREE sales, milestones
Brief: Santhera Pharmaceuticals H1 Operating Income CHF -6.562 Million
Brief: Santhera Says NXERA Plans To Submit South Korea Marketing Authorization Application 2026
Brief: Santhera Gets Positive CHMP Opinion To Expand Agamree (Vamorolone) Use
Brief: Santhera Pharmaceuticals H1 Operating Income CHF -35.444 Million